

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21068

FolderID:

Folder Title:

Mirable

Stack:

S

Row:

67

Section:

1

Shelf:

3

Position:

2



contacted on 2/23
Spoke w/ a female
co-worker, he is
in Africa

SHIMON BRAND, CEO

January 29, 2000

Ms. Sandra Thurman
Director of National AIDS Policy
The White House

VIA FAX (202) 456-2439

Dear Ms. Thurman:

I am providing you the following information in the hope that you will find it sufficiently interesting to commence further communication with me on the subject.

On January 20th last, my associate, Dr. Davy Koech, the director of the Kenya Medical Research Institute enjoyed a "wonderful lunch hour meeting" with you and your delegation at the Ambassador's residence.

I believe that he discussed the work KEMRI is doing in the field of HIV/AIDS research. KEMRI is presently performing clinical trials under contract with *Mirable, Inc.* for one of my company's products, Trioxolane. The title of the trials is **Dose Range Determination of Trioxolane, KE091/ATX, for Efficacy, Safety and Tolerance in Individuals with Asymptomatic HIV-1 Infection in Kenya**. From interim reports I received from KEMRI, the results are very exciting and promise to produce a low cost drug (less than \$1,000.00 per patient per year), free of toxicity or unwanted side effects.


Indeed we are very excited about KE091/ATX, but it is not the subject of this letter. What I do wish to bring to your attention is the fact that Trioxolane *in vitro* is an excellent spermicide and a very effective viricide agent. **We believe that Trioxolane compounded as a vaginal creme can help stem and reverse the HIV epidemic in Africa.**

In order for us to gain approval for the Trioxolane Vaginal Creme in Kenya and the 21 Sub-Saharan African countries we must undertake extensive and complex clinical trials as soon as possible. I believe that funds earmarked for these trial will be well spent and certainly lie within the scope of the presidents recently declared efforts in eradicating the HIV/AIDS scourge.

Mirable, Inc. - Making People Healthier - 7571 Mulholland Drive, Los Angeles
Telephone: 323-876-6546 - Fax: 323-876-6896 - e-mail: ShimBrand@aol.com

I would be delighted to supply you with any information you may require regarding Trioxolane and our work with KEMRI in the HIV/AIDS research.

With warm regards,

A handwritten signature in black ink, appearing to read 'Shimon Brand', with a large, stylized loop at the end.

Shimon Brand



SHIMON BRAND, CEO

January 29, 2000

Ms. Sandra Thurman
Director of National AIDS Policy
The White House

VIA FAX (202) 456-2439

Dear Ms. Thurman:

I am providing you the following information in the hope that you will find it sufficiently interesting to commence further communication with me on the subject.

On January 20th last, my associate, Dr. Davy Koech, the director of the Kenya Medical Research Institute enjoyed a "wonderful lunch hour meeting" with you and your delegation at the Ambassador's residence.


I believe that he discussed the work KEMRI is doing in the field of HIV/AIDS research. KEMRI is presently performing clinical trials under contract with **Mirable, Inc.** for one of my company's products, Trioxolane. The title of the trials is **Dose Range Determination of Trioxolane, KE091/ATX, for Efficacy, Safety and Tolerance in Individuals with Asymptomatic HIV-1 Infection in Kenya**. From interim reports I received from KEMRI, the results are very exciting and promise to produce a low cost drug (less than \$1,000.00 per patient per year), free of toxicity or unwanted side effects.

Indeed we are very excited about KE091/ATX, but it is not the subject of this letter. What I do wish to bring to your attention is the fact that Trioxolane in vitro is an excellent spermicide and a very effective viricide agent. **We believe that Trioxolane compounded as a vaginal creme can help stem and reverse the HIV epidemic in Africa.**

In order for us to gain approval for the Trioxolane Vaginal Creme in Kenya and the 21 Sub-Saharan African countries we must undertake extensive and complex clinical trials as soon as possible. I believe that funds earmarked for these trial will be well spent and certainly lie within the scope of the presidents recently declared efforts in eradicating the HIV/AIDS scourge.

I would be delighted to supply you with any information you may require regarding Trioxolane and our work with KEMRI in the HIV/AIDS research.

With warm regards,

A handwritten signature in black ink, appearing to read 'Shimon Brand', with a large, stylized loop at the end.

Shimon Brand